Description

FYCOMPA 2 MG (1X14)

Indications

FYCOMPA (perampanel) is an antiepileptic medication indicated for the treatment of partial-onset seizures with or without secondary generalization in patients aged 12 years and older. It is also indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients aged 12 years and older. The drug is intended for use in conjunction with other antiepileptic medications to achieve optimal seizure control.

Mechanism of Action

Perampanel, the active ingredient in FYCOMPA, is a non-competitive antagonist of the AMPA subtype of glutamate receptors. By inhibiting the excitatory neurotransmitter glutamate, perampanel decreases neuronal excitability and helps to stabilize electrical activity in the brain. This action is particularly beneficial in the management of seizures, as it reduces the likelihood of seizure initiation and propagation.

Pharmacological Properties

FYCOMPA is characterized by its unique pharmacological profile. It is well-absorbed after oral administration, with peak plasma concentrations typically reached within 0.5 to 1.5 hours. The bioavailability of perampanel is approximately 100%. The drug is extensively metabolized in the liver, primarily by CYP3A4 and CYP2C19 enzymes, leading to the formation of inactive metabolites. The elimination half-life of perampanel is approximately 105 hours, allowing for once-daily dosing. FYCOMPA is primarily excreted via feces, with a minor portion eliminated through urine.

Contraindications

FYCOMPA is contraindicated in patients with a known hypersensitivity to perampanel or any of the excipients in the formulation. Caution should be exercised in patients with a history of psychiatric disorders, as perampanel may exacerbate these conditions. Additionally, the use of FYCOMPA is not recommended in patients with severe hepatic impairment, as the drug’s metabolism may be significantly affected.

Side Effects

Common side effects associated with FYCOMPA include dizziness, drowsiness, fatigue, irritability, and weight gain. Other potential side effects may include nausea, vomiting, and ataxia. Serious adverse reactions can occur, such as psychiatric symptoms including aggression, hostility, and suicidal thoughts. Patients should be monitored for any changes in mood or behavior, particularly during the initiation of therapy or dosage adjustments.

Dosage and Administration

The recommended starting dose of FYCOMPA for adults and adolescents aged 12 years and older is 2 mg once daily, taken orally, preferably at bedtime. Depending on the patient’s response and tolerability, the dose may be titrated in increments of 2 mg at weekly intervals. The maximum recommended dose is 8 mg once daily. It is important for patients to adhere to the prescribed dosage and to consult their healthcare provider before making any changes to their medication regimen.

Interactions

Perampanel is primarily metabolized by CYP3A4 and CYP2C19 enzymes, and its pharmacokinetics may be affected by drugs that induce or inhibit these enzymes. Co-administration with strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampicin) may decrease the plasma concentration of perampanel, potentially reducing its efficacy. Conversely, strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase perampanel levels, leading to an increased risk of adverse effects. Patients should inform their healthcare provider of all medications they are taking to avoid potential drug interactions.

Precautions

Prior to initiating treatment with FYCOMPA, a thorough assessment of the patient’s medical history should be conducted, particularly concerning any history of psychiatric disorders or substance abuse. Patients should be advised to avoid alcohol and other central nervous system depressants while taking FYCOMPA, as these substances may exacerbate sedation and increase the risk of adverse effects. Additionally, caution should be exercised in patients with a history of hepatic impairment, as dose adjustments may be necessary.

Clinical Studies

Clinical studies have demonstrated the efficacy of FYCOMPA in reducing seizure frequency in patients with partial-onset seizures and primary generalized tonic-clonic seizures. In a pivotal Phase III trial, patients receiving FYCOMPA as adjunctive therapy experienced a statistically significant reduction in seizure frequency compared to those receiving placebo. The results supported the use of FYCOMPA in combination with other antiepileptic medications, highlighting its role in comprehensive seizure management. Long-term studies have also indicated that FYCOMPA can maintain its efficacy over extended periods, providing sustained control of seizures in patients.

Conclusion

FYCOMPA 2 MG (1X14) represents a valuable addition to the therapeutic arsenal for managing epilepsy, particularly for patients with partial-onset and primary generalized tonic-clonic seizures. Its unique mechanism of action and favorable pharmacokinetic profile allow for effective seizure control when used in conjunction with other antiepileptic medications. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure safe and effective use. Patients should engage in open communication with their healthcare providers to optimize their treatment and address any concerns regarding their therapy.